Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Preferred Stock Liabilities (2020)

Terns Pharmaceuticals filings provide 1 years of Preferred Stock Liabilities readings, the most recent being $30.0 million for Q4 2020.

  • Quarterly Preferred Stock Liabilities changed N/A to $30.0 million in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $30.0 million through Dec 2020, changed N/A year-over-year, with the annual reading at $30.0 million for FY2020, N/A changed from the prior year.
  • Preferred Stock Liabilities hit $30.0 million in Q4 2020 for Terns Pharmaceuticals, down from $73.0 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $73.0 million in Q2 2020 and bottomed at $13.9 million in Q1 2020.